Augustine Therapeutics NV
Gaston Geenslaan 1
3001 Leuven
BE
Augustine Therapeutics NV
Foundation date
12/03/2019
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
Augustine Therapeutics focuses on the development of new medicines to treat severe debilitating diseases with high unmet need, in particular Charcot-Marie-Tooth disease (CMT) as well as other peripheral neuropathies. Augustine Therapeutics completed a seed financing round of €4.2 million in December 2019 with the support of VIB, V-Bio Ventures and PMV joined by Advent France Biotechnology and the Gemma Frisius Fund. Augustine Therapeutics is a drug discovery company building a portfolio of first-in-class drugs rooted in the ground-breaking research on neurodegenerative disorders of Prof. Ludo Van Den Bosch, Prof. Joris De Wit and Prof. Bart De Strooper at VIB.
Upcoming events
All events-
0411 '24
BIO-Europe® 2024 - 30th Annual International Partnering Conference
Event by: EBD Group -
1012 '24
Next-Generation Synthetic Biology
Event by: VIB -
0312 '24
BioFIT 2024
Event by: Eurasanté
Latest news
More newsJobs by Augustine Therapeutics NV
More jobsMore info?
Ellen Telleir
Communication Coordinator